Triazolophthalazines

1. A compound of formula I

in which

R1 is —U-A, in which

U is a direct bond, or methylene (—CH 2 —),

A is phenyl, pyridinyl, thienyl, or R11- and/or R111-substituted phenyl, in which

R11 is 1-4C-alkyl, halogen, trifluoromethyl, hydroxyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, phenoxy, 1-4C-alkoxycarbonyl, morpholino, or di-1-4C-alkylamino,

R111 is 1-4C-alkoxy, halogen, hydroxyl, or 1-4C-alkyl,

R2 is —N(H)—S(O) 2 R3, —S(O) 2 —N(R4)R5, tetrazol-5-yl, or R6-substituted tetrazol-5-yl, in which

R3 is 1-4C-alkyl, phenyl, R31- and/or R311-substituted phenyl, phenyl-1-4C-alkyl, —N(R32)R33, Har1, or Har2, in which

R31 is 1-4C-alkoxy, halogen, nitro, 1-4C-alkyl, trifluoromethyl, hydroxyl, 1-4C-alkoxycarbonyl, 3-7C-cyloalkylmethoxy, 1-4C-alkylcarbonyl, amino, morpholino, mono- or di-1-4C-alkylamino, or 1-4C-alkylcarbonylamino,

R311 is 1-4C-alkoxy, halogen, 1-4C-alkyl, hydroxyl, or 3-7C-cyloalkylmethoxy,

or R31 and R311 together are a 1-2C-alkylenedioxy group,

R32 is hydrogen, or 1-4C-alkyl,

R33 is 1-4C-alkyl,

or R32 and R33 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

Het1 is optionally substituted by R34, and is a 3- to 7-membered monocyclic fully saturated heterocyclic ring radical comprising the nitrogen atom, to which R32 and R33 are bonded, and optionally one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur, in which

R34 is 1-4C-alkyl,

Har1 is optionally substituted by R35, and is a 5-membered monocyclic aromatic heteroaryl radical comprising one to four heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulphur, whereby said Har1 radical is bonded to the parent molecular group via a ring carbon atom, in which

R35 is 1-4C-alkyl,

Har2 is optionally substituted by R36, and is a 6-membered monocyclic aromatic heteroaryl radical comprising one or two nitrogen atoms, whereby said Har2 radical is bonded to the parent molecular group via a ring carbon atom, in which

R36 is 1-4C-alkyl, 1-4C-alkoxy, amino, morpholino, or mono- or di-1-4C-alkylamino,

R4 is hydrogen, 1-4C-alkyl, pyridinyl, or pyrimidinyl,

R5 is hydrogen, or 1-4C-alkyl,

or R4 and R5 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring radical Het2 or Har3, in which

Het2 is optionally substituted by R41, and is a 3- to 7-membered monocyclic fully saturated heterocyclic ring radical comprising the nitrogen atom, to which R4 and R5 are bonded, and optionally one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur, in which

R41 is 1-4C-alkyl,

Har3 is optionally substituted by R42, and is a 5-membered monocyclic unsaturated, aromatic heteroaryl radical comprising the nitrogen atom, to which R4 and R5 are bonded, and optionally one further nitrogen atom, in which

R42 is 1-4C-alkyl,

R6 is 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, aryl, or aryl-1-4C-alkyl, in which

aryl is phenyl, or R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkyl, 1-4C-alkoxy, hydroxyl, or halogen,

R62 is 1-4C-alkyl, 1-4C-alkoxy, or halogen,

or a salt thereof.

2. A compound of formula I according to claim 1 , in which

R1 is —U-A, in which

U is a direct bond, or methylene (—CH 2 —),

A is phenyl, pyridinyl, thienyl, di-(1-4C-alkoxy)-phenyl, or R11-substituted phenyl, in which

R11 is 1-4C-alkyl, halogen, trifluoromethyl, hydroxyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, phenoxy, 1-4C-alkoxycarbonyl, morpholino, or di-1-4C-alkylamino,

R2 is —N(H)—S(O) 2 R3, or —S(O) 2 —N(R4)R5, in which

R3 is 1-4C-alkyl, phenyl, R31-substituted phenyl, phenyl-1-4C-alkyl, —N(R32)R33, Har1, or Har2, in which

R31 is 1-4C-alkoxy, 1-4C-alkyl, 1-4C-alkylcarbonyl, morpholino, mono- or di-1-4C-alkylamino, or 1-4C-alkylcarbonylamino,

R32 is hydrogen, or 1-4C-alkyl,

R33 is 1-4C-alkyl,

or R32 and R33 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

Het1 is a 3- to 7-membered monocyclic fully saturated heterocyclic ring radical comprising the nitrogen atom, to which R32 and R33 are bonded, and optionally one further heteroatom selected from the group consisting of N(R34), oxygen and sulphur, in which

R34 is 1-4C-alkyl,

Har1 is a 5-membered monocyclic aromatic heteroaryl radical comprising one or two heteroatoms independently selected from the group consisting of N(R35), oxygen and sulphur, whereby said Har1 radical is bonded to the parent molecular group via a ring carbon atom, in which

R35 is 1-4C-alkyl,

Har2 is optionally substituted by R36, and is pyridinyl, in which

R36 is morpholino, or mono- or di-1-4C-alkylamino,

R4 is hydrogen, 1-4C-alkyl, pyridinyl, or pyrimidinyl,

R5 is hydrogen, or 1-4C-alkyl,

or R4 and R5 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring radical Het2 or Har3, in which

Het2 is optionally substituted by R41, and is a 3- to 7-membered monocyclic fully saturated heterocyclic ring radical comprising the nitrogen atom, to which R4 and R5 are bonded, and optionally one further heteroatom selected from the group consisting of N(R41), oxygen and sulphur, in which

R41 is 1-4C-alkyl,

Har3 is optionally substituted by R42, and is pyrrol-1-yl or imidazol-1-yl, in which

R42 is 1-4C-alkyl,

or a salt thereof.

3. A compound of formula I according to claim 1 , in which

R1 is —U-A, in which

U is a direct bond, or methylene (—CH 2 —),

A is phenyl, pyridinyl, thienyl, dimethoxyphenyl, or R11-substituted phenyl, in which

R11 is methyl, tertbutyl, chlorine, fluorine, bromine, trifluoromethyl, hydroxyl, methoxy, ethoxy, trifluoromethoxy, phenoxy, methoxycarbonyl, morpholino, or dimethylamino,

R2 is —N(H)—S(O) 2 R3, or —S(O) 2 —N(R4)R5, in which

R3 is 1-4C-alkyl, R31-substituted phenyl, phenyl-1-4C-alkyl, —N(R32)R33, Har1, or Har2, in which

R31 is 1-4C-alkoxy, 1-4C-alkyl, 1-4C-alkylcarbonyl, or 1-4C-alkylcarbonylamino,

R32 is 1-4C-alkyl,

R33 is 1-4C-alkyl,

or R32 and R33 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

Het1 is pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, or 4N-(1-4C-alkyl)-piperazin-1-yl,

Har1 is thienyl, oxazolyl, thiazolyl, or 1N-(1-4C-alkyl)-imidazolyl,

Har2 is substituted by R36, and is pyridinyl, in which

R36 is morpholin-4-yl,

R4 is hydrogen, 1-4C-alkyl, pyridinyl, or pyrimidinyl,

R5 is hydrogen, or 1-4C-alkyl,

or R4 and R5 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring radical Het2 or Har3, in which

Het2 is pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, or 4N-(1-4C-alkyl)-piperazin-1-yl,

Har3 is pyrrol-1-yl or imidazol-1-yl,

or a salt thereof.

4. A compound of formula I according to claim 1 , in which

R1 is —U-A, in which

U is a direct bond, or methylene (—CH 2 —),

A is phenyl, 4-methoxy-phenyl, 2-methoxy-phenyl, 2-bromo-phenyl, 4-bromo-phenyl, 2-fluoro-phenyl, 2-(trifluoromethyl)-phenyl, 3-methoxy-phenyl, 3-bromo-phenyl, 3-fluoro-phenyl, or 3-(trifluoromethyl)-phenyl;

R2 is —N(H)—S(O) 2 R3, or —S(O) 2 —N(R4)R5, in which

R3 is 1-2C-alkyl, R31-substituted phenyl, phenyl-1-2C-alkyl, —N(R32)R33, Har1, or Har2, in which

R31 is 1-2C-alkoxy, 1-2C-alkyl, 1-2C-alkylcarbonyl, or 1-2C-alkylcarbonylamino,

R32 is 1-2C-alkyl,

R33 is 1-2C-alkyl,

or R32 and R33 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

Het1 is morpholin-4-yl,

Har1 is thienyl, or 1N-methyl-imidazolyl,

Har2 is substituted by R36, and is pyridinyl, in which

R36 is morpholin-4-yl,

R4 is hydrogen, 1-2C-alkyl, or pyrimidinyl,

R5 is hydrogen, or 1-2C-alkyl,

or R4 and R5 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring radical Het2, in which

Het2 is morpholin-4-yl,

or a salt thereof.

5. A compound of formula I according to claim 1 , in which

R1 is phenyl, 4-methoxy-phenyl, 2-bromo-phenyl, 4-bromo-phenyl, or 2-dimethylamino-phenyl,

R2 is attached in the meta or para position with respect to the binding position in which the phenyl ring is bonded to the amino group of the triazolophthalazine scaffold, and is —N(H)—S(O) 2 R3, or —S(O) 2 —N(R4)R5,

in which

R3 is methyl, 3-(R31)-phenyl, 4-(R31)-phenyl, benzyl, —N(R32)R33, Har1, or Har2, in which

R31 is methoxy, methyl, acetyl, or acetylamino,

R32 is methyl,

R33 is methyl,

or R32 and R33 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

Het1 is morpholin-4-yl,

Har1 is thien-2-yl or 1 N-methyl-imidazol-4-yl,

Har2 is 6-(morpholin-4-yl)-pyridin-3-yl,

either

R4 is hydrogen, and

R5 is hydrogen, or

R4 is methyl, and

R5 is methyl, or

R4 is pyrimidinyl, and

R5 is hydrogen,

or R4 and R5 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring radical Het2, in which

Het2 is morpholin-4-yl;

or a salt thereof.

6. A compound of formula I according to claim 1 , in which

R1 is phenyl, 4-methoxy-phenyl, 2-methoxy-phenyl, 2-bromo-phenyl, 4-bromo-phenyl, 2-fluoro-phenyl, 2-(trifluoromethyl)-phenyl, or 2-dimethylamino-phenyl,

R2 is attached in the meta or para position with respect to the binding position in which the phenyl ring is bonded to the amino group of the triazolophthalazine scaffold, and is —N(H)—S(O) 2 R3, or —S(O) 2 —N(R4)R5,

in which

R3 is methyl, 3-(R31)-phenyl, 4-(R31)-phenyl, benzyl, —N(R32)R33, Har1, or Har2, in which

R31 is methoxy, methyl, acetyl, or acetylamino,

R32 is methyl,

R33 is methyl,

or R32 and R33 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

Het1 is morpholin-4-yl, pyrrolidin-1-yl, or piperidin-1-yl,

Har1 is thien-2-yl or 1 N-methyl-imidazol-4-yl,

Har2 is 6-(morpholin-4-yl)-pyridin-3-yl,

either

R4 is hydrogen, and

R5 is hydrogen,

or

R4 is methyl, and

R5 is methyl,

or

R4 is pyrimidinyl, and

R5 is hydrogen,

or R4 and R5 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring radical Het2, in which

Het2 is morpholin-4-yl;

or a salt thereof.

7. A compound of formula I according to claim 1 , in which

R1 is 4-methoxy-benzyl,

R2 is —N(H)—S(O) 2 R3, —S(O) 2 —N(R4)R5, tetrazol-5-yl, or R6-substituted tetrazol-5-yl, in which

R3 is —N(R32)R33, in which

R32 is methyl

R33 is methyl,

R4 and R5 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring radical Het2, in which

Het2 is piperidin-1-yl,

R6 is methyl,

or a salt thereof.

8. A compound of formula I according to claim 1 , in which

R1 is —U-A, in which

U is a direct bond, or methylene (—CH 2 —),

A is phenyl, pyridinyl, thienyl, or R11- and/or R111-substituted phenyl, in which

R11 is 1-4C-alkyl, halogen, trifluoromethyl, hydroxyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, phenoxy, 1-4C-alkoxycarbonyl, morpholino, or di-1-4C-alkylamino,

R111 is 1-4C-alkoxy, halogen, hydroxyl, or 1-4C-alkyl,

R2 is, tetrazol-5-yl, or R6-substituted tetrazol-5-yl, in which

R6 is 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, aryl, or aryl-1-4C-alkyl, in which

aryl is phenyl, or R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkyl, 1-4C-alkoxy, hydroxyl, or halogen,

R62 is 1-4C-alkyl, 1-4C-alkoxy, or halogen,

or a salt thereof.

9. A compound of formula I according to claim 1 , in which

R1 is —U-A, in which

U is a direct bond, or methylene (—CH 2 —),

A is phenyl, pyridinyl, thienyl, di-(1-4C-alkoxy)-phenyl, or R11-substituted phenyl, in which

R11 is 1-4C-alkyl, halogen, trifluoromethyl, hydroxyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, phenoxy, 1-4C-alkoxycarbonyl, morpholino, or di-1-4C-alkylamino,

R2 is, tetrazol-5-yl, or R6-substituted tetrazol-5-yl, in which

R6 is 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, or aryl-1-4C-alkyl, in which

aryl is phenyl, or R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkyl, 1-4C-alkoxy, hydroxyl, or halogen,

R62 is 1-4C-alkyl, 1-4C-alkoxy, or halogen,

or a salt thereof.

10. A compound of formula I according to claim 1 , in which

R1 is —U-A, in which

U is a direct bond, or methylene (—CH 2 —),

A is phenyl, pyridinyl, thienyl, dimethoxyphenyl, or R11-substituted phenyl, in which

R11 is methyl, tertbutyl, chlorine, fluorine, bromine, trifluoromethyl, hydroxyl, methoxy, ethoxy, trifluoromethoxy, phenoxy, methoxycarbonyl, morpholino, or dimethylamino,

R2 is, tetrazol-5-yl, or R6-substituted tetrazol-5-yl, in which

R6 is 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, or phenyl-1-4C-alkyl,

or a salt thereof.

11. A compound of formula I according to claim 1 , in which

R1 is 4-methoxy-phenyl, 2-methoxy-phenyl, 2-bromo-phenyl, 4-bromo-phenyl, 2-fluoro-phenyl, 2-(trifluoromethyl)-phenyl, 3-methoxy-phenyl, 3-bromo-phenyl, 3-fluoro-phenyl, or 3-(trifluoromethyl)-phenyl;

R2 is, tetrazol-5-yl, or 2-(R6)-2H-tetrazol-5-yl, in which

R6 is 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, or phenyl-1-4C-alkyl,

or a salt thereof.

12. A compound of formula I according to claim 1 , in which

R1 is 4-methoxy-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 2-bromo-phenyl, 3-bromo-phenyl, 4-bromo-phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, 2-(trifluoromethyl)-phenyl, or 3-(trifluoromethyl)-phenyl;

R2 is, tetrazol-5-yl, or 2-(R6)-2H-tetrazol-5-yl, in which

R6 is 1-4C-alkyl,

or a salt thereof.

13. A compound of formula I, selected from the group consisting of:

Thiophene-2-sulfonic acid {4-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-amide,

1-Methyl-1H-imidazole-4-sulfonic acid {4-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-amide,

N-{4-[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}methanesulfonamide,

N-{4-[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-1-phenyl-methanesulfonamide,

3-Methoxy-N-{4-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-benzenesulfonamide,

Morpholine-4-sulfonic acid {4-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-amide,

[4-(N,N-dimethylsulfamoyl)-phenyl]-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine,

N-{4-[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

N-{3-[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-4-methyl-benzenesulfonamide,

4-Methoxy-N-{3-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-benzenesulfonamide,

1-Methyl-1H-imidazole-4-sulfonic acid {3-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-amide,

4-Acetyl-N-{3-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-benzenesulfonamide,

[3-(N,N-dimethylsulfamoyl)-phenyl]-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine,

3-Methoxy-N-{3-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-benzenesulfonamide,

N-{3-[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-1-phenyl-methanesulfonamide,

6-Morpholin-4-yl-pyridine-3-sulfonic acid {3-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-amide,

Thiophene-2-sulfonic acid {3-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-amide,

N-(4-{3-[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenylsulfamoyl}-phenyl)-acetamide,

N-{3-[3-(4-Methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-methanesulfonamide,

4-[3-(4-Methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-benzenesulfonamide,

4-[3-(4-Methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-N-pyrimidin-2-yl-benzenesulfon amide,

[3-(4-Methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine,

3-[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-benzenesulfonamide,

3-[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-N,N-dimethyl-benzenesulfonamide,

[3-(4-Methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-3-(morpholine-4-sulfonyl)-phenyl]-amine,

[3-(N,N-dimethylsulfamoyl)-phenyl]-[3-(2-N,N-dimethylamin-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine,

[3-(N,N-dimethylsulfamoyl)-phenyl]-[3-(2-bromo-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine,

[3-(N,N-dimethylsulfamoyl)-phenyl]-[3-(4-bromo-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine,

[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-[3-(pyrrolidine-1-sulfonyl)-phenyl]-amine,

[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-[3-(piperidine-1-sulfonyl)-phenyl]-amine,

3-(N,N-dimethylsulfamoyl)-phenyl]-[3-(2-fluoro-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine,

3-(N,N-dimethylsulfamoyl)-phenyl]-[3-(2-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine,

[3-(N,N-dimethylsulfamoyl)-phenyl]-[3-(2-trifluoromethyl-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine,

Morpholine-4-sulfonic acid {3-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-amide,

[3-(4-Methoxy-benzyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-[4-(piperidine-1-sulfonyl)-phenyl]-amine,

[3-(N,N-dimethylsulfamoyl)-phenyl]-[3-(4-methoxy-benzyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine,

N-{3-[3-(4-Methoxy-benzyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-methanesulfonamide,

3-[3-(4-Methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-benzonitrile,

4-[3-(4-Methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-benzonitrile,

[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl[-]3-(2H-tetrazol-5-yl)-phenyl]-amine,

[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-[4-(2H-tetrazol-5-yl)-phenyl]-amine,

[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl[-]3-(2-methyl-2H-tetrazol-5-yl)-phenyl]-amine,

[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl[-]4-(2-methyl-2H-tetrazol-5-yl)-phenyl]-amine,

3[3-(4-Methoxybenzyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-benzonitrile,

[3-(4-Methoxy-benzyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl[-]3-(2H-tetrazol-5-yl)-phenyl]-amine,

[3-(4-Methoxy-benzyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-[3-(2-methyl-2H-tetrazol-5-yl)-phenyl]-amine,

and the salts of these compounds.

14. A pharmaceutical composition comprising one or more compounds of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable auxiliary and/or excipient.

15. A method for treating pneumonia or acute respiratory distress syndrome (ARDS) in septic shock in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of formula I as claimed in claim 1 , or a pharmaceutically acceptable salt thereof.

16. A method for treating an acute or chronic airway disorder in a patient in need thereof, wherein the acute or chronic airway disorder is selected from the group consisting of rhinitis, bronchitis, bronchial asthma, emphysema and chronic obstructive pulmonary disease (COPD), comprising administering to said patient a therapeutically effective amount of a compound of formula I as claimed in claim 1 , or a pharmaceutically acceptable salt thereof.